Clinical Trial

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Study acronym: PREVAIL
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-01-20; most recent amendment 2024-06-03.
Status change: Recruiting → Active, Not Recruiting 2024-06-03
Status change: Not Yet Recruiting → Recruiting 2022-02-21
Trial Details
NCT Number NCT05202509
Lead Sponsor NewAmsterdam Pharma
Collaborators: Monash University
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 9,541 participants
Start Date 2022-02-07
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-06-04